# US 2021/0171576 A1 · Methods for treating cancer with acyldepsipeptide analogs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171576 A1
- Document ID: US20210171576A1
- Status: Published application
- Kind: A1
- Application number: 15/734,185
- Filed: 2019-06-03
- Published: 2021-06-10
- Earliest claimed: 2018-06-01
- Inventors: Walid A. Houry; Robert A. Batey; Mark F. Mabanglo; Jordan D. Goodreid; Keith S. Wong
- Web page: https://patentgrep.com/patent/US20210171576A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- C07K 7/54: with at least one abnormal peptide link in the ring
- A61P 35/00: Antineoplastic agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods and uses for treating cancer in a subject are provided. In particular, the present disclosure provides methods and uses relating to treating a subject with cancer by activating human mitochondrial CIpP (HsCIpP). The present disclosure further provides methods and uses of an acyldepsipeptide (ADEP) analog that activates HsCIpP in the subject in need thereof.

## Claims

### Claim 1

A method for treating a subject having cancer, comprising administering a therapeutically effective amount of an acyldepsipeptide (ADEP) analog to the subject in need thereof.

### Claim 2 (depends on 1)

The method of claim 1 , wherein the ADEP analog is ADEP-01, ADEP-02, ADEP-03, ADEP-04, ADEP-05, ADEP-06, ADEP-07, ADEP-08, ADEP-09, ADEP-10, ADEP-11, ADEP-12, ADEP-13, ADEP-14, ADEP-15, ADEP-16, ADEP-17, ADEP-18, ADEP-19, ADEP-20, ADEP-21, ADEP-22, ADEP-23, ADEP-24, ADEP-25, ADEP-26, ADEP-27, ADEP-28, ADEP-29, ADEP-30, ADEP-31, ADEP-32, ADEP-33, ADEP-34, ADEP-35, ADEP-36, ADEP-37, ADEP-38, ADEP-39, ADEP-40, ADEP-41, ADEP-42, ADEP-43, ADEP-44, ADEP-45, or ADEP-46.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ADEP analog is ADEP-01 , ADEP-02, ADEP-04, ADEP-06, ADEP-10, ADEP-13, ADEP-14, ADEP-15, ADEP-17, ADEP-20, ADEP-25, ADEP-28, ADEP-29, ADEP-30, ADEP-32, ADEP-37, ADEP-38, or ADEP-41.

### Claim 4 (depends on 1)

The method of claim 1, wherein the ADEP analog is ADEP-14, ADEP-17, ADEP-28, ADEP-29, ADEP-30, ADEP-32, ADEP-37, or ADEP-38.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ADEP analog activates protease activity of human mitochondrial CIpP (HsCIpP), and wherein the protease activity is at least 0.87 as measured by the relative degradation (RD) index at 25 μM of the ADEP analog, optionally at least 0.9, optionally at least 0.95.

### Claim 6 (depends on 1)

The method of claim 1, wherein the protease activity is at least 0.74 as measured by the RD index at 5 μM of the ADEP analog, optionally at least 0.8, optionally at least 0.85.

### Claim 7 (depends on 1)

The method of claim 1, wherein the protease activity is at least 0.2 as measured by the RD index at 1 μM of the ADEP analog, optionally at 0.5, optionally at least 0.75, optionally at least 0.8.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cancer is breast cancer, prostate cancer, colon cancer, liver cancer, uterus cancer, thyroid cancer, lung cancer, lymph nodes cancer, bladder cancer, ovary cancer, stomach cancer, testis cancer, brain cancer, skin cancer, pancreatic cancer, acute myeloid leukemia, kidney cancer, cervical cancer, osteosarcoma, or neuroblastoma.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cancer is breast cancer, kidney cancer, cervical cancer, osteosarcoma, or neuroblastoma.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cancer is metastatic.

### Claim 11 (depends on 10)

The method of claim 10, wherein the metastatic cancer is breast cancer.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is human.

### Claim 13 (depends on 1)

The method of claim 1, wherein the ADEP analog is administered subcutaneously, intraperitoneally, intravenously, topically, or orally.

### Claim 14

A compound for use in treating a subject having a cancer, wherein the compound is a therapeutically effective amount of an acyldepsipeptide (ADEP) analog.

### Claim 15 (depends on 14)

The compound of claim 14, wherein the ADEP analog is ADEP-01, ADEP-02, ADEP-03, ADEP-04, ADEP-05, ADEP-06, ADEP-07, ADEP-08, ADEP-09, ADEP-10, ADEP-11, ADEP-12, ADEP-13, ADEP-14, ADEP-15, ADEP-16, ADEP-17, ADEP-18, ADEP-19, ADEP-20, ADE P-21, ADEP-22, ADEP-23, ADEP-24, ADEP-25, ADEP-26, ADEP-27, ADEP-28, ADEP-29, ADEP-30, ADEP-31, ADEP-32, ADEP-33, ADEP-34, ADEP-35, ADEP-36, ADEP-37, ADEP-38, ADEP-39, ADEP-40, ADEP-41, ADEP-42, ADEP-43, ADEP-44, ADEP-45, or ADEP-46.

### Claim 16 (depends on 14)

The compound of claim 14, wherein the ADEP analog is ADEP-01, ADEP-02, ADEP-04, ADEP-06, ADEP-10, ADEP-13, ADEP-14, ADEP-15, ADEP-17, ADEP-20, ADEP-25, ADEP-28, ADEP-29, ADEP-30, ADEP-32, ADEP-37, ADEP-38, or ADEP-41.

### Claim 17 (depends on 14)

The compound of claim 14, wherein the ADEP analog is ADEP-14, ADEP-17, ADEP-28, ADEP-29, ADEP-30, ADEP-32, ADEP-37, or ADEP-38.

### Claim 18 (depends on 14)

The compound of claim 14, wherein the ADEP analog activates protease activity of human mitochondrial CIpP (HsCIpP), and wherein the protease activity is at least 0.87 as measured by the relative degradation (RD) index at 25 μM of the ADEP analog, optionally at least 0.9, optionally at least 0.95.

### Claim 19 (depends on 14)

The compound of claim 14, wherein the protease activity is at least 0.74 as measured by the RD index at 5 μM of the ADEP analog, optionally at least 0.8, optionally at least 0.85.

### Claim 20 (depends on 14)

The compound of claim 14, wherein the protease activity is at least 0.2 as measured by the RD index at 1 μM of the ADEP analog, optionally at 0.5, optionally at least 0.75, optionally at least 0.8.

### Claim 21 (depends on 14)

The compound of claim 14, wherein the cancer is breast cancer, prostate cancer, colon cancer, liver cancer, uterus cancer, thyroid cancer, lung cancer, lymph nodes cancer, bladder cancer, ovary cancer, stomach cancer, testis cancer, brain cancer, skin cancer, pancreatic cancer, acute myeloid leukemia, kidney cancer, cervical cancer, osteosarcoma, or neuroblastoma.

### Claim 22 (depends on 14)

The compound of claim 14, wherein the cancer is metastatic.

### Claim at position 23

23-26. (canceled)

### Claim 27

An acyldepsipeptide (ADEP) analog, wherein the ADEP analog is ADEP-01, ADEP-02, ADEP-03, ADEP-04, ADEP-05, ADEP-06, ADEP-07, ADEP-08, ADEP-09, ADEP-10, ADEP-11, ADEP-12, ADEP-13, ADEP-14, ADEP-15, ADEP-16, ADEP-17, ADEP-18, ADEP-19, ADEP-20, ADEP-21, ADEP-22, ADEP-23, ADEP-24, ADEP-25, ADEP-26, ADEP-27, ADEP-28, ADEP-29, ADEP-30, ADEP-31, ADEP-32, ADEP-33, ADEP-34, ADEP-35, ADEP-36, ADEP-37, ADEP-38, ADEP-39, ADEP-40, ADEP-41, ADEP-42, ADEP-43, ADEP-44, ADEP-45, or ADEP-46, or a variant or a derivative thereof.
